Treatment of patients with destructive arthritis with certolizumab pegol. Certolizumab pegol is a new anti-TNF-alpha inhibitor which has been approved for the treatment of rheumatoid arthritis since October 2009. In two individual case reports a remission of therapy refractive arthritis was achieved by administration of certolizumab pegol. (SpringerLink) T. Schmeiser. Zeitschrift fur Rheumatologie. June 9 2010. (Also see: Treatments for RAand TNF Inhibitors)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Treatment of patients with destructive arthritis with certolizumab pegol
No replies to this topic